Roger Tell
Chief Tech/Sci/R&D Officer bij ISOFOL MEDICAL AB
Actieve functies van Roger Tell
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| ISOFOL MEDICAL AB | Chief Tech/Sci/R&D Officer | 01-02-2019 | - |
| Chief Executive Officer | 22-06-2023 | 09-01-2024 | |
| VIVESTO AB | Director/Board Member | 25-05-2022 | - |
Loopbaan van Roger Tell
Eerdere bekende functies van Roger Tell
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Corporate Officer/Principal | - | 01-02-2019 |
Opleiding van Roger Tell
| Karolinska Institutet | Doctorate Degree |
Statistieken
Internationaal
| Zweden | 5 |
Operationeel
| Chief Executive Officer | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
| Corporate Officer/Principal | 1 |
Sectoraal
| Health Technology | 4 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| VIVESTO AB | Health Technology |
| ISOFOL MEDICAL AB | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Health Technology |
- Beurs
- Insiders
- Roger Tell
- Ervaring
